nitroglycerin

Taken together, CQG inhibited PI3K/Akt signaling pathway to reduced neuroinflammation, and modulated metabolic pathway of glycerophospholipid metabolism in MH. The findings of this study offer novel insights into the mechanisms underlying the therapeutic effects of CQG, highlighting its potential clinical application in treatment of MH.

P2, N=26, Not yet recruiting, Simon Fraser University | Trial completion date: Feb 2025 --> Feb 2026 | Trial primary completion date: Feb 2025 --> Feb 2026

P=N/A, N=248, Not yet recruiting, Tongji Medical College, Huazhong University of Science and Technology; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Tec

P4, N=86, Not yet recruiting, The First Affiliated Hospital of Henan University of Chinese Medicine; The First Affiliated Hospital of Henan University of Chinese Medicine

P=N/A, N=80, Recruiting, Alexandria University | Trial completion date: Aug 2024 --> Jan 2025 | Trial primary completion date: Aug 2024 --> Dec 2024

P=N/A, N=32, Active, not recruiting, NYU Langone Health | Recruiting --> Active, not recruiting | N=100 --> 32

P1, N=12, Active, not recruiting, Vanderbilt University | Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Jul 2024 --> Jul 2025

These findings suggest that the mechanical barrier of HA is the major reason responsible for the resistance developed during prolonged anti-angiogenesis in EGC. Incorporating PEGPH20 into the existing treatment regimen is promising to improve outcomes for patients with EGC.

P=N/A, N=60, Completed, Fayoum University Hospital

P=N/A, N=10, Recruiting, Montefiore Medical Center | Suspended --> Recruiting | Trial completion date: Dec 2024 --> Jun 2026 | Trial primary completion date: Dec 2024 --> Jun 2026

P=N/A, N=10, Suspended, Montefiore Medical Center | N=20 --> 10

136,572-09-3 BOSS and others were identified as potential targeted drugs for endometrial carcinoma targeting ferroptosis. Our study has shown that ferroptosis-related genes CDKN2A, NRAS and TFRC are diagnostic markers of endometrial carcinoma, and 136,572-09-3 BOSS, methyprylon BOSS, daunorubicin CTD 00005752, nitroglycerin BOSS and dUTP BOSS, IRON BOSS, Imatinib mesylate BOSS, 2-Butanone BOSS, water BOSS, and L-thyroxine BOSS may be potential therapeutic drugs.

P1, N=25, Recruiting, University Hospital, Basel, Switzerland | Trial completion date: Mar 2025 --> Aug 2025 | Trial primary completion date: Dec 2024 --> May 2025

P2, N=26, Not yet recruiting, Simon Fraser University | Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Feb 2024 --> Feb 2025

P=N/A, N=44, Completed, University of Pennsylvania | N=25 --> 44

P2, N=256, Not yet recruiting, Thomas Jefferson University

P=N/A, N=50, Recruiting, Kaohsiung Medical University Chung-Ho Memorial Hospital

P=N/A, N=74, Recruiting, Instituto Nacional de Cancerologia de Mexico

P=N/A, N=80, Recruiting, Alexandria University | Not yet recruiting --> Recruiting

P2, N=43, Completed, Dr. D. Robert Siemens | Unknown status --> Completed | Phase classification: P3 --> P2

P=N/A, N=20, Suspended, Montefiore Medical Center | Trial completion date: Dec 2023 --> Dec 2024 | Enrolling by invitation --> Suspended | Trial primary completion date: Dec 2023 --> Dec 2024

P2/3, N=60, Enrolling by invitation, Alexandria University

We provide novel evidence linking nutrition and metabolism with migraine.

This information would be useful for clinical practice. www.chictr.org.cn, Identifier ChiCTR2200062282.

We investigated here whether the combination of doxorubicin, a standard chemotherapy in TNBC with glyceryltrinitrate (GTN), a nitric oxide (NO) donor, could overcome chemotherapy resistance and highlight the mechanisms involved in a mouse model of TNBC. (4) We have identified a new combination enhancing the immune-mediated anticancer therapy in a TNBC mouse model through the reprograming of PMN-MDSCs towards a less immunosuppressive phenotype. These findings prompt the testing of GTN combined with chemotherapies as an adjuvant in TNBC patients experiencing treatment failure.

Subsequent coronary angiogram was aborted due to hypertensive emergency and flash pulmonary edema for which he required IV hydralazine 20 mg, furosemide 80 mg, labetalol 30 mg, verapamil 5 mg, nitroglycerin 800 mg bolus then gtt at 100 mcg/min to achieve hemodynamic stability. He reached the preoperative BP goal after up titration of doxazosin to 12 mg daily and carvedilol to 25 mg twice daily...He was successfully discharged on metoprolol succinate 25 mg, spironolactone 25 mg and losartan 25 mg daily.Clinical Lessons: Preoperative management of pheochromocytoma involves alpha-adrenergic blockade followed by beta-adrenergic blockade to target a BP of <130/80...Abstracts presented at a news conference are embargoed until the date and time of the news conference. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*

For newly diagnosed BMs, adding chemotherapy, EGFR-TKIs, and other innovative systemic agents (temozolomide, nitroglycerin, endostar, enzastaurin, and veliparib) to radiotherapy did not significantly prolong OS than radiotherapy alone; whereas radiotherapy + nitroglycerin showed significantly better CNS-PFS and ORR...For previously treated BMs, pembrolizumab + chemotherapy, nivolumab + ipilimumab, and cemiplimab significantly prolonged OS than chemotherapy alone...The value of surgery should also be emphasized. The result should be further confirmed by RCTs.

She was treated with aspirin, heparin, amlodipine, topical nitroglycerin and analgesics. She had a gradual recovery except for a small necrotic area over the right 4th digit. However, surgical intervention was avoided.

Moreover, NTG synergistically enhanced the cytotoxicity and cell growth inhibition induced by pemetrexed in NSCLC cells; these effects were associated with AKT and ERK1/2 inactivation and, consequently, Rad52 downregulation in H520 and H1975 cells. The results provide a rationale for combining NTG and pemetrexed in lung cancer treatment to improve lung cancer control.

BP was elevated to 143/113, refractory to bolus anti-hypertensives and a nitroglycerin infusion; he ultimately required a nicardipine infusion for blood pressure control...Labs at the time of diagnosis included Cr elevated to 1.6 mg/dl, troponin peak 1.3 ng/ml, NT-proBNP 291 pg/ml, TSH 3, free plasma metanephrine 108 pg/ml, normetanephrine 7,987 pg/ml, fractionation of norepinephrine >1,200 pg/ml in the serum and >517 mcg/g in the urine, epinephrine 251 pg/ml serum and 21 mcg/g in urine, dopamine 1,144 pg/ml in serum, and chromogranin A 2,058 ng/ml...His BP was controlled on lisinopril and doxazosin with stable BP outpatient of 114/68...Chemotherapy and radiation can be offered as some cases are not ameable to surgery. Performing germline genetic testing should also be considered in such cases.

The concurrent administration of NTG and radiotherapy improves iORR and ICPFS among NSCLC patients with BM. The benefit is particularly significant in the EGFRm patient subgroup.

We used a subtoxic dose of carboplatin and/or recombinant IL-6 to activate the JAK2/STAT3 signaling pathway and its functional outcomes. We discovered that GTN inhibits the activation of JAK2, the upstream activator of STAT3, and mediates the S-nitrosylation of JAK2. Finally, the effect of GTN (Nitronal) on lung metastasis was investigated to assess its antitumor activity in vivo.

Co-treatment with nitroglycerin partly rescued tumor progression, probably by ROS inhibition, while mebendazole completely blocked anticancer activity of the disulfiram and metformin combination, most likely by NF-κB stimulation. Combination of disulfiram with metformin may be used as an effective and safe candidate for novel nontoxic adjuvant and relapse prevention anticancer therapy.

P2, N=223, Completed, Dutch Society of Physicians for Pulmonology and Tuberculosis | Recruiting --> Completed | Trial completion date: Aug 2014 --> Aug 2020